Skip to main content
Signal8
Ryali Sriram profile photo

Sriram Ryali

CIK: 0001762893

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Caribou Biosciences, Inc. logo
CRBU

Caribou Biosciences, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Caribou Biosciences, Inc. logo
    CRBU

    Caribou Biosciences, Inc.

    Feb 20, 2026
    Award(A)
    Direct
    55K shares-
  • Caribou Biosciences, Inc. logo
    CRBU

    Caribou Biosciences, Inc.

    Jan 29, 2025
    Purchase(P)
    Direct
    17.4K shares at avg. $1.42$25K
  • Caribou Biosciences, Inc. logo
    CRBU

    Caribou Biosciences, Inc.

    Jan 10, 2025
    Award(A)

    Option to purchase Common Stock

    Direct
    300K shares-

1-3 of 3

About Ryali Sriram

Ryali Sriram (SEC CIK 0001762893) files insider reports with the SEC as Chief Financial Officer of Caribou Biosciences, Inc. (CRBU).

Signal8 holds 4 ownership filings by Ryali Sriram (1 Form 3, 3 Form 4), filed between Jan 10, 2025 and Feb 20, 2026. Those filings report 3 transactions, from Jan 10, 2025 to Feb 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ryali Sriram's filings is in BERKELEY, CA.

Recent filings by Ryali Sriram

  • Feb 20, 2026: Grant or award of CRBU shares (Form 4, code A).
  • Jan 29, 2025: Open-market purchase of CRBU shares (Form 4, code P).
  • Jan 10, 2025: Grant or award of CRBU derivative securities (Form 4, code A).

Other insiders filing for Caribou Biosciences, Inc. (CRBU)

How to read Form 4 transaction codes